You are here

CEI Weekly: Is There a Future for Generic Biotech Crops?

CEI Weekly

Title

CEI Weekly: Is There a Future for Generic Biotech Crops?

FEATURE: Is There a Future for Generic Biotech Crops?

Usually when patents expire, new generic markets are allowed to develop. But in the case of crop biotechnology, current U.S. regulatory policy could prevent a market of affordable generic biotech seeds. CEI Senior Fellow Greg Conko explains the situation and proposes regulatory reforms in a new CEI Issue Analysis: "Is There a a Future for Generic Biotech Crops? Regulatory Reform Is Needed for a Viable Post-Patent Industry."

 

The Federal Department of Higher Spending and Higher Local Taxes

David Bier's op-ed in The Washington Examiner

 

What Do The War on Cancer and Climate Modeling Have in Common?

Bill Frezza's op-ed in Forbes

 

Field of Cash: If You Offer, They Will Take

Trey Kovacs' op-ed in The Daily Caller

 

Chicago Strike Shows Unions Corrupt Teachers, Harm Students

Matt Patterson's op-ed in The Washington Examiner


Unions Stack the Deck Against Job Creation

Matt Patterson & Crissy Brown's op-ed in The Washington Times

 

Market Demand Knocks Down Regulatory Barriers in Kansas City Fiber Deployment

Fred Campbell's op-ed in Ars Technica

 

'Bipartisan' Board Donates to Dems Overwhelmingly

John Berlau's citation in The Washington Free Beacon

 

Privacy Bill Requires Search Warrants for Email, Cell Phone Tracking

Ryan Radia's citation in CNET

 

PBS Newshour Omits Obama's Support for Blasphemy Law

Hans Bader's citation on HotAir

 

CEI PODCAST

September 27, 2012: The Future of Generic Biotech Crops

Senior Fellow Greg Conko discusses his newpaper, “Is There a Future for Generic Biotech Crops? Regulatory Reform Is Needed for a Viable Post-Patent Industry.” Patents will soon expire for several popular biotech crops, opening the way for cheaper generic versions. But because, unlike prescription drugs, biotech crops have to be re-approved every few years, the future of generic biotech crops is very much in doubt. Conko recommends getting rid of re-approval requirements to put them on the same footing as other products.

 

BEST OF THE BLOGS

Study Finds Diisononyl Phthalate Safe For Toys

By Angela Logomasini

 

Scapegoating Free Speech

By Hans Bader

 

In Rejecting EPIC's Petition on TSA's Strip-Search Machines, Court Effectively Orders Rulemaking Timetable

By Marc Scribner

 

State Pension Bailout Threat

By Hans Bader